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How Was the Hypothesis Tested?
The authors 3 performed rapid amplification of complementary DNA ends on RNA isolated from murine adult ventricles to identify a cluster of lncRNAs, which the authors named myosin heavy-chain-associated RNA transcripts (Myheart, or Mhrt) , from the Myh7 loci. By using quantitative polymerase chain reaction with reverse transcription (RT-qPCR), the authors examined the expression levels of Mhrt in various murine tissues and compared the expression levels of Mhrt to the mRNA levels of Myh6 and Myh7 in murine hearts at different ages. The authors also performed RNA in situ hybridization to determine the cellular distribution of Mhrt in adult murine heart tissues.
To study the role of Mhrt in cardiac hypertrophy and heart failure, the authors induced pressure overload by subjecting mice to transaortic constriction (TAC) and used RT-qPCR to measure the expression levels of Mhrt at different time points after TAC. The authors then focused on the most abundant Mhrt in murine adult ventricles (Mhrt779) and generated transgenic mice overexpressing Mhrt779 (Tg779 mice) in a doxycycline-dependent and cardiomyocyte-specific manner. The authors subjected Tg779 mice to TAC to see whether overexpression of Mhrt779 could protect the heart from TACinduced hypertrophy and failure.
In addition, the authors investigated the mechanism by which Mhrt expression is repressed during cardiac stress. Their group had previously reported that the Brg1-Hdac-Parp chromatin repressor complex was activated by cardiac stresses to repress Myh6 expression and induce Myh7 expression, changing the Myh6/Myh7 ratio in failing hearts. 2 To test whether Brg1 could repress the Mhrt promoter, the authors generated an episomal luciferase reporter construct containing the murine Mhrt promoter and cotransfected this construct with a construct expressing murine Brg1 into Brg1-deficient SW13 cells (derived from a human carcinoma of the adrenal cortex) for luciferase reporter assays. The authors performed chromatin immunoprecipitation assays to confirm that Brg1, Hdac2/9, and Parp1 can bind to the Mhrt promoter in the luciferase reporter episome and in TAC-treated murine hearts. 2 To see whether Mhrt779 could physically interact with Brg1, the authors conducted RNA immunoprecipitation using TACtreated murine adult ventricles (from wild-type or Tg779 mice) or neonatal ventricles expressing Brg1, as well as RNA immunoprecipitation and electric mobility shift assays using recombinant murine Brg1 proteins and in vitro transcribed Mhrt779. Moreover, the authors conducted strand-specific reverse transcription polymerase chain reaction analysis of total RNA from human heart tissue to identify a human MHRT transcript from the MYH7 loci and used RT-qPCR to examine the expression levels of human MHRT in control and hypertrophic, ischemic, or idiopathic cardiomyopathy tissues.
Principal Findings
5′ and 3′ rapid amplification of complementary DNA ends analysis on RNA isolated from murine adult ventricles revealed the presence of a cluster of Mhrt lncRNAs (ranging in length from 709 to 1147 nucleotides) originating from the Myh7 loci. Using RT-qPCR and RNA in situ hybridization, the authors demonstrated that these Mhrt lncRNAs are specifically expressed in the murine adult heart, particularly in the nuclei of myocardial cells and not endocardial or epicardial cells. Expression levels of Mhrt are low in fetal hearts, but increase as the hearts mature and as the ratio of Myh6 to Myh7 expression increases.
The authors showed that expression levels of Mhrt were decreased by 48% to 68% in the hearts of TAC-operated mice compared with sham-operated mice, and the decrease was observed as early as 2 days after TAC and lasted for ≥42 days after TAC. Of note, the decrease in the levels of Mhrt correlated with the TAC-induced decrease in the ratio of Myh6 to Myh7 expression, suggesting that Mhrt lncRNAs may play a role in regulating the switch of Myh6/Myh7 expression during cardiac stress. To further investigate the role of Mhrt in cardiac hypertrophy and heart failure, the authors focused on Mhrt779, the most abundantly expressed Mhrt lncRNA in murine adult ventricles. The authors found that doxycyclinetreated Tg779 mice subjected to TAC were able to maintain the expression levels of Mhrt779 at prestress levels. These mice also exhibited an attenuated hypertrophic response (such as reduced ventricle/body-weight ratio, decreased cardiomyocyte size, and decreased atrial natriuretic factor [Anf], brain natriuretic peptide [Bnp], sarcoplasmic reticulum Ca 2+ -ATPase isoform 2 [Serca2], transforming growth factor β-1 [Tgfb1], and osteopontin [Opn] mRNA levels), reduced cardiac fibrosis, improved fractional shortening, and normalized left ventricular size compared with doxycycline-treated wild-type mice 6 weeks after TAC. In addition, the authors tested the effect of treating Tg779 mice with doxycycline 1 to 2 weeks after the initiation of TAC to induce the expression of Mhrt779 after the onset of cardiac hypertrophy. The authors showed that this experimental design also resulted in reduced ventricle/body-weight ratio and improved fractional shortening in the doxycycline-treated Tg779 mice compared with doxycycline-treated wild-type mice 8 weeks after TAC. Taken together, these results suggest that Mhrt lncRNAs serve a protective role during cardiac stress, antagonizing the development of cardiac hypertrophy, and heart failure.
To study the mechanism by which Mhrt expression is repressed during cardiac stress, the authors hypothesized that Brg1, which has been previously reported to be activated by cardiac stresses, 2 could bind to the Mhrt promoter and repress its transcription. Supporting this hypothesis, the authors found no reduction in the expression levels of Mhrt lncRNAs in Brg1-null hearts in response to TAC, suggesting that the presence of Brg1 is crucial for the repression of Mhrt expression during cardiac stress. By performing reporter assays in Brg1-deficient SW13 cells with an episomal luciferase reporter construct containing the murine Mhrt promoter, the authors demonstrated that transfection of Brg1 decreased luciferase activity and that this decrease was abrogated in the presence of either trichostatin-A (a Hdac inhibitor) or PJ-34 (a Parp inhibitor). These findings suggest that the Brg1-Hdac-Parp chromatin repressor complex is involved in repressing Mhrt promoter activity. Consistent with these findings, chromatin immunoprecipitation analysis in SW13 cells transfected with the episomal luciferase reporter containing the Mhrt promoter, as well as in TAC-treated murine hearts, 2 demonstrated that Brg1, Hdac2/9, and Parp1 can bind to the Mhrt promoter. The authors also performed RNA immunoprecipitation using TAC-treated murine adult ventricles (from wild-type or Tg779 mice) or neonatal ventricles expressing Brg1 to show that Mhrt779 coimmunoprecipitated with Brg1, providing further evidence that Mhrt779 and Brg1 can physically interact with each other. In addition, the authors were able to show using RNA immunoprecipitation that recombinant murine Brg1 protein can directly coimmunoprecipitate with in vitro transcribed Mhrt779, indicating that the interaction between Mhrt779 and Brg1 is direct and does not require any other factors. Moreover, the authors performed electric mobility shift assays utilizing maltose-binding proteintagged recombinant proteins that contained the Brg1 helicase domain and a biotin-labeled Mhrt779 probe to demonstrate that Mhrt779 can specifically interact with the helicase domain of Brg1. Amylose pull-down assays revealed that the Brg1 helicase domain was able to pull-down nucleosomal Myh6 promoter DNA, but not the naked Myh6 promoter DNA, and that this pull-down was disrupted by the presence of Mhrt779. Complementary chromatin immunoprecipitation and reporter assay experiments in rat ventricular cardiomyocytes and SW13 cells, utilizing either a chromatinized or nonchromatinized Myh6 promoter-luciferase reporter construct, demonstrated that Brg1 could bind to and repress the Myh6 promoter only when it was chromatinized and that the presence of Mhrt779 disrupted the ability of Brg1 to bind to and repress the chromatinized Myh6 promoter. Together with the pull-down results, these cellular studies suggest that the Brg1 helicase binds to chromatinized, but not naked, DNA targets and that Mhrt can interfere with this binding through its interaction with the helicase domain.
To see whether Mhrt can affect the ability of Brg1 to regulate the expression of its target genes, the authors performed chromatin immunoprecipitation analysis in hearts isolated from doxycycline-treated Tg779 mice subjected to TAC and found a reduction in Brg1 binding to the Myh6, Myh7, and Opn promoters compared with doxycycline-treated wildtype mice 2 weeks after TAC. This reduction in binding was associated with a corresponding decrease in the ratio of Myh7 to Myh6 expression. By conducting reporter assays in neonatal rat cardiomyocytes with luciferase reporter constructs containing the murine Myh6, Myh7, or Opn promoter, the authors demonstrated that transfection of Brg1 decreased the activity of the Myh6 promoter and increased the activity of the Myh7 and Opn promoters. However, these changes in promoter activity were abrogated when a vector expressing Mhrt779 was also cotransfected into the cells. Taken together, these results suggest that the interaction between Brg1 and Mhrt interferes with the ability of Brg1 to bind to and regulate the expression of its genomic targets, such as Myh6 and Myh7. In this way, Mhrt can prevent Brg1 from inducing aberrant changes in gene expression during cardiac stress. Interestingly, using strand-specific reverse transcription polymerase chain reaction analysis of total RNA from human heart tissue, the authors discovered that the human MYH7 loci also encoded a MHRT RNA that bears resemblance to murine Mhrt in both primary sequence and secondary structure. Similar to its murine counterpart, the expression levels of human MHRT, as determined by
